Quo vadis, biotech? (Part 2)

Those following the financial markets and the valuation of biotechnology companies recently might find themselves perplexed. Towards the end of 1999, during which the availability of capital for biotech initial public offerings and for private investment rounds seemingly withered, the markets sudden...

Full description

Saved in:

Bibliographic Details
Published in:	Drug Discovery Today Vol. 6; no. 1; pp. 21 - 26
Main Author:	Drews, Jurgen
Format:	Book Review Journal Article
Language:	English
Published:	Oxford Elsevier Ltd 2001 Elsevier Science
Subjects:	Biological and medical sciences Biotechnology General pharmacology Industry Investment Medical sciences Pharmaceutical Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Revenue Industry Biotechnology Revenue Pharmaceutical Investment Financial market Review Recombinant protein Pharmaceutical industry Gene therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Those following the financial markets and the valuation of biotechnology companies recently might find themselves perplexed. Towards the end of 1999, during which the availability of capital for biotech initial public offerings and for private investment rounds seemingly withered, the markets suddenly turned around and gave the biotechnology industry its biggest bonanza ever.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-Review-3 content type line 23 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	1359-6446 1878-5832
DOI:	10.1016/S1359-6446(00)01611-1